Since dietary protein increases urinary dopamine (DA) excretion in animals, this study was undertaken to assess the role of DA production in the acute changes in renal function following protein ingestion in man. Excretion of DA, sodium, potassium, water, solute, and creatinine were measured in six normal men in 30-min intervals over 5 h after oral ingestion of protein and/or carbidopa, an inhibitor of DA formation from 3,4-dihydroxyphenylalanine (DOPA). Overall, protein increased urinary DA 50% (P = 0.031) while carbidopa reduced it 70% (P < 0.0001), although suppression of DA excretion by carbidopa was not uniform over the 5 h of observation. Carbidopa doubled the level of DOPA in venous plasma and greatly magnified the DOPA response to protein. Inhibition of decarboxylase activity reduced excretion of sodium, potassium, solute and water after protein ingestion. These results indicate that extraneuronal DOPA decarboxylation in kidney contributes to acute protein-induced changes in renal function in man and suggest a general role for the decarboxylation of circulating DOPA in the expression of dopaminergic effects on the kidney in vivo.
Introduction
Dopamine (DA 1)1 is known to exert several effects on renal function including, prominently, an increase in renal blood flow (1-3), a decrease in sodium reabsorption (4) , and an increase in potassium and phosphate excretion (5, 6) . These effects of DA to promote renal blood flow and sodium excretion contribute to its therapeutic utility in the treatment of hypotension and congestive heart failure. In addition, evidence has accumulated within the past few years implicating endogenous DA in the regulation of salt excretion (7) (8) (9) , though the nature of the renal dopaminergic system remains obscure. Recent studies from this 1. Abbreviations used in this paper: ANOVA, analysis of variance; CH2OCI, free water clearance; Con.,Cl, osmolar clearance; CrC0, creatinine clearance, DA, dopamine; DOPA, 3,4-dihydroxyphenylalanine; E, epinephrine; NE, norepinephrine. urinary excretion of DA in the rat (10, 1 1). Because of the possibility that the relationship between protein intake and urinary DA might help elucidate the nature of the peripheral dopaminergic system, and because of the current interest in the relationship between protein intake, renal function and the pathogenesis of progressive renal failure (12) , the present study was undertaken.
In this investigation the effect of a single protein meal on urinary DA excretion and renal function was determined in six normal subjects both before and after inhibition of DA biosynthesis with carbidopa. The results demonstrate that protein ingestion enhances DA formation by a mechanism involving the extraneuronal decarboxylation ofcirculating 3,4-dihydroxyphenylalanine (DOPA), the amino acid precursor of DA, probably within kidney. Since some ofthe effects ofprotein ingestion on renal function are antagonized by blockade of DA biosynthesis, these results support the hypothesis that renal responses to a protein meal are mediated, in part, by renal DA production and that one component of a dopaminergic regulatory system in kidney involves the extraneuronal decarboxylation of circulating DOPA to DA.
Methods
Study design. Six male subjects (ages 25-43 yr) with normal renal function and no history of hypertension were tested on the Clinical Research Center at the Beth Israel Hospital. The protocol was approved by the Committee on Clinical Investigations, New Procedures, and New Forms of Therapy at Beth Israel Hospital and informed consent was obtained from all subjects. The study employed a 2 X 2 factorial design with protein (presence or absence) and carbidopa (presence or absence) as the two factors. Subjects thus underwent a series of 4 studies with a variable sequence of testing in each subject and a 10-14-d interval between any two tests.
Protocol. Subjects were admitted to the Clinical Research Center the evening prior to testing and were studied after an overnight fast. In the morning at least 30 min elapsed between insertion of an intravenous catheter in an antecubital vein for blood sampling and collection ofbasal samples. Urine was obtained from spontaneous voidings. To ensure frequent voiding during the test procedure all studies were performed in the presence of a water diuresis, following an oral load of 20 ml/kg given at time zero. Urine and blood samples were collected at 30-min intervals over 5 h; pulse and blood pressure were also measured every 30 min. Although subjects stood to void, all blood samples were obtained with the subjects supine immediately before standing, -25 min after the previous voiding.
In addition to the water load, in the two protein tests subjects consumed 60 g of protein over 15-25 min Urine catecholamine analysis. Urine samples were acidified to a pH between 2 and 3 and stored at -20'C prior to assay. Unless otherwise specified below all chemicals were obtained from Fisher Scientific Co. (Fair Lawn, NJ).
Analysis of catecholamines in urine followed the method of Smedes et al. (13) as modified by Macdonald and Lake (14) . To 1 .0-ml aliquots of urine was added 100 Ml of the internal standard (3,4-dihydroxybenzylamine, DHBA; Aldrich Chemical Co., Milwaukee, WI) in 50 mM H3PO4; pH was adjusted to 7.5 as necessary. This mixture was then added to 30-50 mg ofSepralyte SCX (Analytichem International, Harbor City, CA) previously activated by exposure to 1 ml of 0.2 M Na2HPO4, pH 7.5, and mixed vigorously. After removal of the supernatant, the SCX was washed twice with water. Catecholamines were eluted with I ml of 1 M NaH2PO4, pH 2.9. This supernatant was transferred quantitatively into screw-topped, glass tubes. Approximately 0.5 ml of NH4Cl/ NH40H buffer containing 0.2% (wt/vol) diphenylboric acid ethanolamine complex (Aldrich Chemical Co.) and 0.5% EDTA was added to bring pH to 8.6. After addition of 2.5 ml of n-heptane containing 1% (vol/vol) octanol and 0.35% (wt/vol) tetraoctylammonium bromide (Fluka AG, Buchs, Switzerland) tubes were capped and shaken. The heptane supernatant was then transferred to a centrifuge tube and I ml octanol and 0.2 ml of0.4 N acetic acid containing 10-15 mg glutathione were added. After mixing and centrifugation, aliquots of the acetic acid phase were injected onto a chromatographic system for quantitation of catecholamines.
This system was composed of a pump (6000A; Millipore, Waters Associates, Chromatography Division, Milford, MA), an automatic sample injector (Waters Intelligent Sample Processor, WISP; Millipore), a reverse-phase column (250 X 4 mm, Bio-Sil ODS-5S; Bio-Rad Laboratories, Richmond, CA) and a glassy carbon amperometric detector (LC-4B/17; Bioanalytical Systems, West Lafayette, IN). The mobile phase was an acetate-citrate buffer composed of sodium acetate (100 mM), sodium hydroxide (60 mM) and citric acid (30 mM, all three from Mallinckrodt, Inc., Paris, KY) at pH 5.3 containing 4-6% methanol, 80 mM EDTA and 0.95 mM sodium octyl sulfonate (Aldrich Chemical Co. or Eastman Kodak, Rochester, NY) flowing at a rate of 1.0 ml/min. The detector potential was set at +0.65 V vs. Ag/AgCl reference electrode. Detector response was quantitated by peak height utilizing an integrating recorder (3390A, Hewlett-Packard Co., Avondale, PA). Intraassay coefficients of variation for urine samples (corrected for recovery) are 4-6% for epinephrine, norepinephrine and dopamine; interassay coefficients of variation are 6-7% for all three catecholamines.
Plasma DOPA and norepinephrine assay. Plasma for DOPA and norepinephrine (NE) determinations was collected in chilled, heparinized tubes containing reduced glutathione ( Biochemical analyses. Serum and urine levels of creatinine and of sodium and potassium were measured by computerized analyzer (SMAC II, Technicon Instruments, Inc., Tarrytown, NY). Serum and urine osmolalities were determined by freezing point depression (Osmometer, Advanced Instruments, Needham Heights, MA). Plasma aldosterone was measured by standard radioimmunoassay (Coat-a-Count, Diagnostic Products Corporation, Los Angeles, CA). Clearances for creatinine, free water and solute were calculated according to standard formulae.
Data analysis. Data are presented as means±SEM, unless otherwise stated. The study followed a 2 X 2 factorial design with protein (0/+) and carbidopa (0/+) as the two main factors. In addition, since each subject participated in all four parts of the study, "subjects" was considered a third factor crossed with both protein and carbidopa. Data analysis was therefore based upon a 3-factor analysis ofvariance (ANOVA), mixed model, with protein (+/0) and carbidopa (+/0) as fixed factors and "subjects," a random factor (16) . ANOVA also included an additional factor "time" (fixed) for repeated measures within a test where appropriate. Homogeneity of variances within the ANOVA was assessed by Hartley's test (17) and goodness of fit of the data to the ANOVA model by the Wilk-Shapiro and Kolmogorov-Smirnov tests (16) . Calculations were performed with BMDPC Statistical Software, Los Angeles, CA (18) .
In analysis of correlation, correlation coefficients were calculated after determination that both variables were normally distributed (16) . Following "z" transformation (with bias correction), correlation coefficients were analyzed by ANOVA. Test mean correlation coefficients represent reverse transformation of the average of z transformed data.
Results
Effect ofprotein and carbidopa on urinary catecholamine excretion. Urinary excretion of DA, NE, and epinephrine (E) over the 5 h collection period in each of the four tests is shown in Table I . While neither protein ingestion nor carbidopa administration affected urinary NE or E, DA excretion was altered by both. Protein increased urinary DA excretion both in the presence and absence of carbidopa (P = 0.031), while carbidopa lowered urinary DA excretion by >60% whether protein was present or not (P = 0.0001). The temporal profile ofDA excretion over the 5-h test periods, illustrated in Fig. 1 , provides further insight into these effects of protein and carbidopa on urinary DA excretion. As shown in Fig. 1 , although urinary DA increased slightly at the end of the test period in the two studies without carbidopa, in the two carbidopa studies the rise in urinary DA was progressive over the 5 h of observation. The temporal characteristics of DA excretion in these studies thus suggest: first, Table II , revealed a highly significant antinatriuretic effect of carbidopa (P = 0.009), but only a marginally significant proteininduced natriuresis (P < 0.1). When the data were analyzed following logarithmic transformation, however, the main effects of both protein and carbidopa were statistically significant (P < 0.05). The explanation for this difference resides in the fact that among all subjects natriuretic responses to protein were of similar proportion, but not ofsimilar amount. In a mixed model ANOVA, such as the one employed here, the protein variance is compared to the protein X subject variance, the measure of variability among subjects in the effect of protein. When the protein X subject variance is itself statistically significant, as in the analysis of the untransformed sodium excretion data, the Data in parentheses refer to the results of analysis of UNaV data following logarithmic transformation. Mean Na excretion in each test is presented as the antilogarithm of mean log (Na) and is, therefore, the geometric mean of Na excretion in the 6 subjects.
risk of type II (false negative) errors increases. The significance of this protein X subject variation, however, disappears with logarithmic transformation, implying that the effect of protein is not additive among all subjects, but multiplicative (i.e., proportional), a condition that favors the application of ANOVA to log-transformed data. For potassium excretion the main effects of protein and carbidopa were of borderline significance, although the interaction between protein and carbidopa was statistically significant (P = 0.041). (Results of ANOVA following logarithmic transformation ofurinary potassium were equivalent to those of the untransformed data presented in Table II.) One difference of note between sodium and potassium excretion is apparent from Fig. 3 . While potassium excretion was relatively stable over the 5 h of observation, sodium excretion rose progressively. Since this temporal pattern in urinary excretion was common to both sodium and DA (Fig. 1) , the relationship between these two was examined more closely. The correlation between sodium and DA was computed for all subjects from the 10 urine samples collected during each test and the 24 correlation coefficients (after "z" transformation) were then analyzed by ANOVA. In The total volumes of urine excreted over the 5 h test periods are presented in Table II and the rates of free water and osmolar clearances for each 30-min interval are shown in Fig. 4 . Urine volumes (in absolute amount or as percent of administered load) were greater following protein ingestion (P < 0.005) and less after carbidopa administration (P < 0.03). Examination of Effect ofprotein and carbidopa on serum creatinine, creatinine excretion, and creatinine clearance. Serum creatinine concentrations (computed for each subject from the mean of all measurements obtained during each 5-h test period) and total creatinine excretion are presented in Table III and the calculated creatinine clearance for each 30-min interval illustrated in Fig.  5 . Serum creatinine levels were, on average, 30% higher following protein ingestion (P = 0.0006) and 7% higher after carbidopa administration (P = 0.028), while basal creatinine values (not shown) did not differ among the four tests. Urinary creatinine excretion was also markedly increased by protein feeding (an average elevation of 56% in the two tests, P = 0.0003). Carbidopa also influenced creatinine excretion, reducing it 3% in the presence of protein and elevating it 15% in its absence (protein X carbidopa interaction, P = 0.031). Protein ingestion raised creatinine clearance (P < 0.05). Although in the presence of protein, carbidopa administration increased serum and reduced urine creatinine, implying a diminution in creatinine clearance, the effect ofcarbidopa on creatinine clearance was not statistically significant. The nonsteady state conditions in the circulating creatinine pool during these studies, however, emphasizes the limitations inherent in the use of creatinine clearance as a measure of glomerular filtration.
Discussion
This study demonstrates that ingestion of a single protein meal acutely increases urinary DA excretion in normal human subjects (Table I, Fig. 1 ); NE and E excretion, in contrast, are not affected. This observation is consistent with data in the rat documenting a rise in urinary DA excretion in response to protein supplementation of a lab chow diet (10) and a diminution in urinary DA with protein restriction (1 1). The available evidence, therefore, indicates that in both man and rodent dietary protein exerts a specific stimulatory effect on urinary DA excretion.
The present study, moreover, provides evidence that the protein-induced augmentation in DA excretion involves the extraneuronal decarboxylation of DOPA since carbidopa reduced urinary DA excretion without affecting urinary NE (Table I, (23) and from the isolated perfused rat kidney (24) demonstrates that DA presented to the kidney is extensively metabolized and not excreted as free DA. Moreover, in previous work (8) , as well as in the present study (Table I) , inhibition of decarboxylation sharply reduced urinary DA excretion. The temporal sequence of changes in plasma DOPA and urinary DA in the presence of carbidopa, summarized in Figs. 1 and 2, provides additional support for the conclusion that the increment in urinary DA excretion following protein ingestion reflects decarboxylation of circulating DOPA. The changes observed in plasma DOPA concentration (Fig. 2) , furthermore, suggest the existence of three distinct phases in the urinary DA response to protein after carbidopa administration: (a) an initial period of effective inhibition of DA formation; (b) a period of less effective blockade due to increased circulating levels of DOPA (since carbidopa is a competitive inhibitor ofthe enzyme); and (c) a final period of declining antagonism of DOPA decarboxylation, as manifested by increasing DA excretion despite falling plasma DOPA levels. The time course of changes in plasma DOPA and urinary DA excretion, in the presence of carbidopa blockade, thus are consistent with the hypothesis that protein induces release of DOPA into the circulation, which in turn leads to an increase in urinary DA excretion.
The finding that inhibition of DOPA decarboxylation (in the absence ofprotein) is associated with a doubling ofthe plasma DOPA concentration indicates the major role played by decarboxylation in the clearance ofcirculating DOPA throughout the body (Fig. 2) . In addition, ingestion of the protein meal, in the setting of impaired clearance of DOPA from plasma due to carbidopa pretreatment, resulted in a further increment (+ 150%) in plasma DOPA concentration. This acute rise in plasma DOPA implies that protein ingestion increases entry of DOPA into the circulation which was only detectable in this study when metabolism of DOPA was blocked by carbidopa. Assuming that protein ingestion induced an equivalent release of DOPA in the absence of carbidopa, the small and statistically insignificant elevation of plasma DOPA following protein (Fig. 2) suggests that the DOPA formed in response to protein ingestion is rapidly removed from plasma and converted to DA and DA metabolites, a portion of which is excreted in the urine (Fig. 1) . Because of the rapidity of this metabolic transformation, the enhanced flux of DOPA through the circulating compartment following protein, as reflected by a rise in venous plasma DOPA concentration, was demonstrable only in the presence of decarboxylase inhibition. Given the fact that in the dog arterial DOPA levels are higher than venous (25) , the possibility exists that greater changes in DOPA concentration after protein may have been demonstrable in arterial plasma.
The increase in plasma DOPA noted following protein intake in carbidopa-treated subjects must originate from either exogenous or endogenous sources. The possibility that DOPA might be a constituent ofthe ingested protein or the product ofsynthesis from tyrosine within gut tissues or by intestinal microflora is unlikely since its content in canned tuna is low and the major metabolic fate for DOPA within the gastrointestinal tract is local Renal Dopamine Response to Oral Protein 1691 E E 0 decarboxylation or conjugation. Moreover, if urinary DA responses to protein or tyrosine reported elsewhere are also indicative of systemic release of DOPA prior to renal decarboxylation, the demonstration that oral tyrosine reproduces in rats the protein-related rise in urinary DA and increases plasma levels and urine content of DA in human subjects (10, 26, 27) , implies that the DOPA response to protein is related to the increased availability of tyrosine. This relationship, however, does not depend upon oral administration since tyrosine delivered parenterally also elevates urine and plasma DA (28, 29). Consequently, a more likely explanation for DOPA entry into the circulation is that it represents an endogenous response to ingestion of the protein load.
Whether this DOPA response to protein is secondary to mass action from the postprandial absorption of tyrosine from the gut or is due to an unidentified neurohumoral reflex must await future studies, but in either case, release of DOPA could theoretically occur from any peripheral tissues capable of converting tyrosine to DOPA. These include melanocytes in which DOPA is formed in the synthesis of melanin by the action of the enzyme tyrosinase and chromaffin tissue (adrenergic nerves, adrenal medulla, and extraadrenal chromaffin tissue, such as paraganglia, carotid body and the like) in which DOPA formation by tyrosine hydroxylase is the first step in catecholamine biosynthesis. Chromaffin tissue, in general, is the more probable source, although a connection between skin pigmentation and plasma DOPA levels was suggested in animals (30) . Since preliminary evidence suggests that the DA response to protein is independent of sympathetic nerves or adrenal innervation (10) , an attractive alternative is the possibility, suggested previously in a different context (31) , that circulating DOPA derives principally from the extraadrenal chromaffin tissue. Identification of the tissue responsible for the DOPA response to protein ingestion clearly requires further study.
The results of studies with carbidopa, as shown in Tables II  and III and in Figs. 3-5, are consistent with DA participation in some of the renal responses to protein ingestion. In particular, the protein-induced elevations in sodium excretion and in osmolar clearance were blunted by pretreatment with carbidopa. The effect on urinary sodium excretion is especially noteworthy. Rapidly accumulating evidence indicates a potentially important role for DA in the regulation of sodium excretion (9, 32) , an effect that may be independent of changes in renal blood flow (4) . The concordant responses of both DA and sodium to protein ingestion and to carbidopa administration and the correlation between urinary DA and sodium in the presence of carbidopa support a role for DA in the regulation of sodium excretion in general, and implicate DA in the natriuresis associated with protein ingestion demonstrated here. Although prompt augmentation of sodium and DA excretion by protein ingestion suggests an intrarenal site for both responses, the early elevations in plasma aldosterone induced by carbidopa raise the possibility that alterations in the secretion of this hormone may also contribute to dopamine-sodium interactions in the context of protein ingestion.
The effects of protein on renal function noted here, and elsewhere (33) , are remarkably similar to the known effects of DA in kidney (1) (2) (3) . Both protein and DA increase clearance of paraamino hippurate, inulin, creatinine and solute, as well as the excretion of sodium and potassium ( [1, 3, 33, 34] Tables II  and III, Figs. 3-5) . Moreover, the renal effects of exogenous DOPA also resemble those associated with protein and DA (35); 
